BRYOSTATIN-1 FOR PROLONGED FIELD CARE
Multi-Organ Protection Against Ischemia-Reperfusion Injury in Combat Settings

“Warfighter health is our mission too.”

CATEGORY

Combat Casualty Care • Anti-Inflammatory Therapeutics • Organ Protection

OPERATIONAL RELEVANCE

Warfighters in austere environments are at high risk for ischemia-reperfusion injury due to delayed evacuation and prolonged field care. Bryostatin-1 is an injectable, field-compatible therapeutic that protects organs and tissue during these critical delays, reducing the onset of systemic inflammation, preserving organ function, and extending treatment windows for definitive care.

TECHNOLOGY SUMMARY

Bryostatin-1 is a potent immunomodulatory agent that prevents multi-organ damage following trauma-induced ischemia and delayed revascularization. It works by modulating immune activation, limiting neutrophil-mediated damage, and maintaining endothelial function. Preclinical models demonstrate preserved viability of kidney, liver, skeletal muscle, and intestine, with strong potential for integration into far-forward and prolonged field care protocols

MILITARY-ALIGNED BENEFITS

• Injectable and field-compatible formulation
• Reduces systemic inflammation (e.g., SIRS) and tissue necrosis
• Enables organ salvage during prolonged evacuation delays
• Supports rapid return-to-duty by minimizing trauma complications
• Broad-spectrum protection across trauma types

USE SCENARIOS

• Combat trauma with delayed revascularization or evacuation
• Forward surgical teams managing crush injuries or blast trauma
• En route care during mass casualty events
• Battlefield use as part of prolonged field care bundles

TECHNOLOGY READINESS & IP

• Technology ID: LSUHSC-S-2020-011
• TRL: 3 – Preclinical proof-of-concept studies in progress
• Patent Status: PCT/US21/46717 (Patent Pending)

COLLABORATIVE OPPORTUNITIES

We are seeking partners to:

• Co-develop and validate Bryostatin-1 in trauma and field care models
• Advance through preclinical and IND-enabling studies
• Explore formulation strategies for austere deployment
• Collaborate on CRADA, SBIR/STTR, or DoD-aligned clinical development pathways
• Integrate into combat casualty care protocols and en route care systems